{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chlamydia-uncomplicated-genital/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"84014645-1e22-51ca-b89b-52cd820d41b7","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 02eb1052-a7ee-4376-b0a5-d81c54bbc5cf --><h2>Changes</h2><!-- end field 02eb1052-a7ee-4376-b0a5-d81c54bbc5cf -->","summary":null,"htmlStringContent":"<!-- begin item ec411abc-236e-4877-9492-b9c70c900fa7 --><!-- begin field 33283b2d-dbae-4093-92c8-4eafc37ae1ce --><p><strong>January 2021</strong> — minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update. </p><!-- end field 33283b2d-dbae-4093-92c8-4eafc37ae1ce --><!-- end item ec411abc-236e-4877-9492-b9c70c900fa7 -->","topic":{"id":"9fd72b23-86c9-5ce5-bbdd-598398d0e8ea","topicId":"7ce33f6f-747f-41e5-b18b-09b2071a7d93","topicName":"Chlamydia - uncomplicated genital","slug":"chlamydia-uncomplicated-genital","lastRevised":"Last revised in January 2021","chapters":[{"id":"0b0636d2-117b-5108-b70c-d19a794db377","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dda664e4-4864-5386-8bf2-ae38fe324071","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6af905a1-8c41-53d9-b5ca-e96a0b2548be","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84014645-1e22-51ca-b89b-52cd820d41b7","slug":"changes","fullItemName":"Changes"},{"id":"66fb5a16-c4f5-562e-9a73-84371e2bbe0d","slug":"update","fullItemName":"Update"}]},{"id":"82517c94-8e8a-5c62-b7d6-670ad4404258","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0f150da5-1397-5e5d-b3dd-c9f2716423aa","slug":"goals","fullItemName":"Goals"},{"id":"f52e0aef-b3ad-5e13-b9ed-d426b4fa2f77","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba38cbe0-ef08-5c56-a1f4-9a962b32ad9f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ced83fa-49d9-5243-8a7f-d942baa4bc1f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5887995c-3455-537d-98cc-b1aeb54144ed","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0f2bffb-9529-57db-a995-191cba2d4e9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"824044f0-a305-5a18-9a1d-bf36875a6ce8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5b8da5a2-6086-58db-9ad4-94fe2eb8bd48","slug":"definition","fullItemName":"Definition"},{"id":"ae31b546-618f-5b61-bf90-254c4868b504","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8cd27f8c-d2f1-57ac-83e8-ed035b78ee51","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"ab8dc958-d4dc-5fef-ac7c-bc2b5865fdbe","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"3a69be68-2fd6-509b-85f4-164afc701ba8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a927a8de-387f-5d99-8924-b8836a37e1a0","slug":"screening-for-chlamydia-in-asymptomatic-men-women","fullItemName":"Screening for chlamydia in asymptomatic men and women"},{"id":"9da777e0-887a-5bb6-af7a-f6f0b986dbf4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"0a0b5d7a-0455-5688-90d5-253f427816b6","slug":"testing-to-confirm-the-diagnosis","fullItemName":"Testing to confirm the diagnosis"}]},{"id":"366e3be0-ac7e-5c90-baed-b3485d6e47ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"9b3c090d-c63e-54c5-8cd1-1f401bc12c7b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0cd2f484-1947-55ec-980e-1d0293ab355e","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"48da76f5-5041-504f-ab81-69b4fe7ff549","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"f100927d-5a5a-5112-bec9-59e5e4d4f040","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07eef3f6-7862-5fc9-b60f-ffa9d201996a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"dacb6886-00ac-5160-9ee9-3ec19959d6ee","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"41a663fd-74e7-5b4b-b936-d4894268ff1f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"34dd7d77-0b55-5661-b769-73e6cade3309","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"ffbef724-e30a-592a-836b-c4c5163d2e15","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0964fb39-dd03-54bb-af48-c376a46d685b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d69f8f7d-515f-5861-85b0-f5d6cf0ecfac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2c32cb59-e5a3-5af2-b976-e11d73a2ea8a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87f9e401-f03f-547f-a524-e2f66bfb58c0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69fd8a3f-633f-5092-85dd-f2220728872d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6af905a1-8c41-53d9-b5ca-e96a0b2548be","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"2ca1abb9-1044-5efc-916f-6f1238afe5a8","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field b0a4fa81-6a51-4fee-861e-12a2d64a1dab --><h3>Previous changes</h3><!-- end field b0a4fa81-6a51-4fee-861e-12a2d64a1dab -->","summary":null,"htmlStringContent":"<!-- begin item 127ac779-0f55-4399-a799-1ec2281d0423 --><!-- begin field 0e8d2b04-9a73-420c-89f4-05808736bb1b --><p><strong>August 2020 </strong>— minor update. A reference to the <em>BASHH Update on the treatment of Chlamydia trachomatis (CT) infection</em> was added to the basis for recommendation in the management section of this topic. </p><p><strong>June 2019</strong> — minor update. Clarification added regarding Test of cure (TOC).</p><p><strong>March 2019 </strong>— minor update. Prescribing information for quinolones updated in line with MHRA, 2019, <em>Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">MHRA, 2019</a>]. </p><p><strong>February 2019 </strong>— minor update. Treatment options refined to doxycycline first line. Removed secondary care advice. </p><p><strong>January 2019 </strong>— minor update. Treatment options updated to be brought in line with updated BASHH guideline 2018, <em>Chlamydia trachomatis treatment</em>. Aortic aneurysm and dissection is now listed as an adverse effect of ciprofloxacin. </p><p><strong>June 2018 </strong>— minor update. Prescribing information updated with information regarding azithromycin interacting with colchicine. </p><p><strong>December 2016</strong> — minor update.</p><ul><li>Uveitis, severe liver injury and exfoliative dermatitis were added as possible adverse effects of ofloxacin, in line with the manufacturer's updated Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI, 2016a</a>]. </li><li>Drug reaction with eosinophilia and systemic symptoms (DRESS) has been added as a possible adverse effect of azithromycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chlamydia-uncomplicated-genital/references/\">ABPI, 2016b</a>].</li></ul><p><strong>June 2016 </strong>— reviewed. A literature search was conducted in June 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><p><strong>May 2011 </strong>— minor update. The recommendation regarding the combined use of antibiotics and combined hormonal contraceptives was changed to reflect the new Faculty of Sexual and Reproductive Healthcare guidance, <em>Drug interactions with hormonal contraception</em> (2011). Issued in June 2011.</p><p><strong>September 2010 </strong>— minor update. The Health Protection Agency (HPA) figures for new diagnoses of chlamydia in 2008/9 have been added. Issued in September 2010.</p><p><strong>August 2009 </strong>— minor update. Advice from the National Institute for Health and Care Excellence (NICE) guideline <em>When to suspect child maltreatment</em> (2009) has been added to this topic. Issued in August 2009.</p><p><strong>November 2008 to May 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. This topic now includes the management of men with uncomplicated genital chlamydia. Azithromycin is now recommended as a first-line antibiotic in women who are pregnant or breastfeeding.</p><p><strong>September 2008 </strong>— minor correction to the Changes section. Issued in September 2008.</p><p><strong>October to December 2005 </strong>— reviewed. Validated in March 2006 and issued in May 2006.</p><p><strong>July 2002 </strong>— reviewed. Validated in October 2002 and issued in December 2002.</p><p><strong>March 2000 </strong>— written. Validated in March 2000 and issued in May 2000.</p><!-- end field 0e8d2b04-9a73-420c-89f4-05808736bb1b --><!-- end item 127ac779-0f55-4399-a799-1ec2281d0423 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}